Patrick Phillips Health Decisions CEO

Patrick Phillips, BSc (Hons), D.Phil. –
Chief Executive Officer

Dr. Patrick Phillips, Chief Executive Officer of Health Decisions, is an experienced and respected clinical development executive and industry leader. He is responsible for executive oversight and strategic leadership of Health Decisions. Before his appointment as CEO, Dr. Phillips served for over two years as Health Decisions’ Vice President of Clinical Affairs. He frequently advises current and potential Health Decisions’ sponsors on program strategy, study design and operational challenges of clinical development projects for drugs, diagnostics and other medical devices.

Dr. Phillips is committed to improving the efficiency of clinical development and establishing Health Decisions as an industry leader in clinical trial planning, design and delivery. He is passionate about driving development efficiencies through end-to-end planning, regulatory insight, adaptive design, and adaptive operations based on in-stream clinical analytics. In addition, Dr. Phillips has made it a strategic priority to extend the reach of precision medicine to a greater range of therapeutic areas and indications through close coordination of diagnostics and drug development programs.

In a career spanning more than 22 years, Dr. Phillips has provided executive oversight and led operational delivery on more than 200 regional and global clinical development projects in all major therapeutic areas, across all phases of drug development as well as a variety of medical device and diagnostics studies. His oversight has included development programs and clinical trials resulting in successful NDAs for four drugs and numerous successful PMA approvals and 510(k) clearances for IVDs.

Read More

Prior to joining Health Decisions in 2014, Dr. Phillips held senior roles with ICON Clinical Research in the United Kingdom and Array Biopharma, GSK and Boehringer Ingelheim in the United States. As Executive Director of Clinical Trial Management at BI, he led US clinical trial delivery across BI’s entire therapeutic portfolio, covering indications in respiratory, endocrine and metabolism, immunology, oncology and CNS.

Among Dr. Phillips’ notable accomplishments is leadership of successful initiatives that enable operational excellence and best practice and deliver consistency, quality and performance in global trials. He frequently speaks at industry events and serves on advisory boards for key industry conferences on clinical development. Dr. Phillips holds a BSc (Hons) in Biochemistry from Liverpool University and a D Phil in Clinical Biochemistry from the University of Oxford in England. As a Postdoctoral Research Associate at Oxford, Dr. Phillips investigated cell signaling networks in oncogenesis and tumor progression. Dr. Phillips’ pro bono work has included serving as a board director for the British American Business Council.

Stephen DeCherney Health Decisions CEO

Stephen DeCherney, MD, MPH – Senior Medical Advisor

Stephen DeCherney, MD, MPH, Senior Medical Advisor at Health Decisions, is a former CEO of Health Decisions and an active member of the Board of Directors. Dr. DeCherney is a respected endocrinologist, pharmaceutical industry leader, clinical development executive and clinical scientist. He provides medical guidance and protocol commentary as necessary on active and planned Health Decisions clinical trials.

Dr. DeCherney is committed to improving the efficiency of clinical development through concepts such as replacing phase 3 trials with a novel phase 2c approach. A member of the Science Policy Committee of the Personalized Medicine Coalition, Dr. DeCherney has made refining study design and operations to provide optimal support for development of precision medicines a top strategic priority at Health Decisions.

For more than 30 years, Dr. DeCherney has led quality improvement initiatives based on statistical process control in both healthcare delivery and research processes. He often provides strategic advice to Health Decisions’ clients and private equity firms, drawing on extensive experience in medical research at multiple levels.

Read More

Dr. DeCherney has managed clinical research staff in 53 countries; provided executive oversight on numerous clinical studies in a wide range of indications; served as Principal Investigator for over 100 clinical trials during 11 years in the Christiana Care Health System in Wilmington, Delaware; and served for five years as a Guest Researcher at the National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health (NIH). He was formerly a senior executive at Quintiles Global Transnational and PRA International.

Dr. DeCherney’s current activities in clinical research include:

  • Reviewing protocols, study designs and operational plans for clinical trials conducted by Health Decisions;
  • Reviewing clinical research  protocols and study design as a member of the University of North Carolina, Chapel Hill, Institutional Review Board;
  • Serving as Trustee, William Harvey Research Institute, of Queen Mary Medical College, London, St Barts and The London Hospitals, London, England;
  • Serving as Chair, University of Delaware Research Foundation;
  • Serving as Trustee, Christiana Care Health System, Delaware.

Board-certified in internal medicine and endocrinology/diabetes, Dr. DeCherney is Clinical Professor of Medicine, University of North Carolina at Chapel Hill. He is also Professor (Adjunct) in the Kenan-Flagler School of Business at the University of North Carolina, where he teaches a course in pharmaceutical economics. Earlier in his career, Dr. DeCherney served as an associate professor at both the University of Delaware and Thomas Jefferson University.

Dr. DeCherney received his medical degree from Temple University in Philadelphia and an MPH, Healthcare Management, from Columbia University School of Public Health.  He completed his residency at the Graduate Hospital of the University of Pennsylvania and performed his endocrinology training at Vanderbilt University. Dr. DeCherney is a graduate of Columbia College, Columbia University in New York City, from which he received a BA in Molecular Biology. Dr. DeCherney has served as director of a variety of organizations and corporations in the United States and the United Kingdom, including the Museum of Life and Science in Durham, North Carolina.


Steve Siferd

Steve Siferd –
Vice President
Sales & Marketing

Steve Siferd is a sales and marketing executive with 20 years of experience in genetics and molecular biology and 14 years of experience managing and delivering molecular diagnostics services in support of clinical development projects for diagnostics and biopharma companies and private and public institutions. Throughout his career, Mr. Siferd has sought to improve human health by leveraging genomics in the clinical development process to achieve better therapies and outcomes. Mr. Siferd is ideally positioned to support clinical development projects that leverage molecular diagnostics to improve patient selection and the ability to demonstrate the safety and efficacy of investigational products.

Mr. Siferd is committed to enabling biopharma companies to utilize precision-medicine techniques to increase the efficiency of clinical development and accelerate delivery of improved treatments to patients with significant unmet medical needs. He has extensive expertise in the application of high-throughput gene expression, genotyping, and next generation sequencing technologies in the clinical development process. His experience ranges from early wet lab responsibilities to executive leadership for genomics business development.

Read More

After beginning his career as a molecular biologist serving over six years in the research genomic testing market, supporting analysis and consultation services for clients from academic, government and commercial institutions, Mr. Siferd identified an unmet need in the emerging precision medicine market. He transitioned to business development, marketing genomics services in progressively responsible roles for three companies. Most recently, Mr. Siferd was Global Head of Genomics Business Development for Q2 Solutions, a joint venture between Quintiles Transnational and Quest Diagnostics.

Mr. Siferd has extensive experience in the application of next generation sequencing technologies in the clinical and diagnostic development process. A recognized expert in precision medicine, he has given invited talks at the National Institutes of Health, Environmental Protection Agency, FDA, and numerous academic institutions. Mr. Siferd holds a BS in Biology from the University of North Carolina at Chapel Hill.